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ABSTRACT  
Objective: Aim of the present study was to compare the effects of pregabalin and nortriptyline on sleep and quality of life in patients of postherpetic 
neuralgia (PHN). 
Methods: The present study was conducted in 48 patients of PHN attending the outpatient department (OPD) of Dermatology, Government Medical 
College Jammu. Based on inclusion/exclusion criteria patients were randomized into two treatment groups. One group received pregabalin 150 
mg/day and the other group was treated with nortriptyline 25 mg/day. The patients were followed up to eight weeks and assessed for Sleep 
(Medical Outcomes Study sleep scale) and quality of life (Euro QOL-5D-5L score). Clinicians Global Impression of Change (CGIC) score and Patient 
Global Impression of Change (PGIC) score were used to evaluate overall clinical improvement.  
Results: Both drugs significantly improved all parameters studied (p<0.0001). On comparison, both drugs had similar effects on sleep and quality of 
life. However, pregabalin was found to be better than nortriptyline at eight weeks on CGIC (p<0.004) and PGIC (p<0.0003) scores.  
Conclusion: Both pregabalin and nortriptyline were equally effective in improving sleep and quality of life. Overall clinical improvement was better 
with pregabalin than nortriptyline at eight weeks. 
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INTRODUCTION 
Postherpetic neuralgia (PHN) is a complication that occurs due to 
reactivation of latent varicella-zoster virus in the sensory ganglia 
and pain persists or recurs four weeks to six months after the 
healing of the skin lesions [1]. Pain follows the typical dermatome 
distribution of the rash [2]. Neuropathic pain is often associated 
with sleep disturbance [3]. Both pain and sleep are known to have a 
negative impact on quality of life [4, 5].  
Treatment of PHN includes topical Lidocaine 5% or capsaicin 8%, 
while systemic therapy is comprised of tricyclic antidepressants 
(TCAs), serotonin-norepinephrine reuptake inhibitors, opioids, 
anticonvulsants and even intrathecal corticosteroids [6]. Among 
them TCAs and antidepressants are most commonly used.  
TCAs are widely prescribed in neuropathies and painful conditions 
like fibromyalgia [7]. TCAs inhibit the reuptake of serotonin and/or 
norepinephrine by presynaptic neuron, and increase their 
concentrations in synaptic cleft. TCAs also desensitize adenylyl 
cyclase, activate GABA-B receptors, down-regulate beta-adrenergic 
and serotonin receptors [8]. 
Amitriptyline is metabolised into nortriptyline, an active metabolite 
by enzyme CYP2C19. Nortriptyline blocks the reuptake of 
norepinephrine more potently than serotonin in comparison to 
amitriptyline. Secondary amines (nortriptyline, desipramine) have 
advantage over tertiary amines (amitriptyline and imipramine) 
because of their better safety profile in terms of sedation, postural 
hypotension, and anticholinergic effects [9, 10]. However, 
nortriptyline in a trial in patients with neuropathic pain has shown 
60% of treated patients showed anticholinergic effects (dry mouth) 
[11]. Therefore all TCAs should be given with caution especially in 
elderly patients because of their anticholinergic effects and cardiac 
toxicity [12]. 
Gabapentinoids (gabapentin and pregabalin) are effective in 
neurological painful conditions including chemotherapy-induced 
peripheral neuropathy (CIPN) [13]. 
Gabapentinoids are widely used in PHN. Pregabalin has been 
approved by FDA for the treatment PHN [14]. Pregabalin binds with 
alpha2-delta protein of presynaptic voltage-gated calcium channels 
causing a decrease in calcium entry resulting in reduced 
depolarisation in the nerve terminals which causes the decline of 
excitatory neurotransmitters release in the pain pathways [15, 16]. 
Pregabalin is preferred over gabapentin because of its better 
bioavailability, and predictable pharmacokinetic properties. 
Pain is known to interfere with sleep and quality of life. Most of 
studies have evaluated the efficacy in ameliorating pain by TCAs and 
anticonvulsants individually in PNH [17]. However, there is a 
scarcity of studies examining effect of TCAs and antidepressants on 
sleep and quality of life in patients of PHN and these parameters are 
important in patients wellbeing. Therefore the present prospective, 
randomized, open label, parallel trial was conducted to evaluate and 
compare the effect of pregabalin and nortriptyline on quality of life 
and sleep interference in patients of PHN.  
MATERIALS AND METHODS 
The study was conducted in the Postgraduate Department of 
Pharmacology in collaboration with Postgraduate Department of 
Dermatology, SMGS Hospital, and Government Medical College 
Jammu after taking approval from the Institutional Ethics 
Committee, GMC Jammu vide no IEC/GMC/2019/829  
A written, informed consent was obtained. The patients reporting to 
the dermatology OPD, diagnosed by the dermatologist as post 
herpetic neuralgia on the basis of a positive history of herpes zoster 
followed by persistent pain (moderate to severe) lasting for more 
than 4 w or recurrence of pain after rash had subsided were 
included. All basic principles of bioethics were followed.  
Inclusion and exclusion criteria 
Patients of both genders ≥ 18 y of age, diagnosed as postherpetic 
neuralgia and having pain at least moderate to severe (VAS score ≥ 
40 mm) and who gave consent were included. While patients with 
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Pregnancy and lactation, Hypersensitivity to any of the test drugs 
cardiac disease, seizure disorder, liver disease, impaired kidney 
functions, already on Gabapentinoids or TCAs, severe depression 
with suicidal tendency, or suffering from any other significant pain 
conditions (HIV infection, diabetic neuropathy, cancer pain, 
fibromyalgia) were excluded from the study. 
Treatment protocol 
Prior to intervention, clinical evaluation with complete medical 
history was done. The eligible patients after meeting the inclusion 
and exclusion criteria were enrolled and randomized into two 
groups (A and B). 
Group A patients received oral Pregabalin 75 mg twice a day at 12 hourly 
intervals for 8 w. Provision of incremental increase (75 mg BD) up to 
maximum 600 mg/day was kept based on patient response and 
tolerability. While Group B patients received oral Nortriptyline 25 mg 
once a day at bedtime for 8 w. Provision of incremental increase (25 mg 
weekly) up to a maximum 100 mg/day was kept on basis of patient 
response and tolerability. Provision of rescue treatment in the form of 
opioid analgesics was kept in patients with inadequate response. 
Patients in both the treatment groups were assessed on follow-up visits 
at 2, 4 and 8 w. Dose selection for both the drugs based on the most 
commonly used dose in earlier studies [18]. 
Sleep interference was assessed on Medical Outcomes Study sleep 
scale (MOS sleep scale). This scale measures six dimensions of sleep, 
including initiation, maintenance (e. g. staying asleep), quantity, 
adequacy, somnolence (e. g. drowsiness) and respiratory 
impairments (e. g. shortness of breath, snoring) [19]. 
Quality of life was assessed on Euro QOL-5D-5L index at baseline and 
end of 8 w. It comprises of 5 dimensions (mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression) and each dimension 
had 5 levels: no problems, slight problems, moderate problems, severe 
problems, and extreme problems. The respondent was asked to indicate 
his/her health state by ticking (or placing a cross) in the box against the 
most appropriate statement in each of the 5 dimensions [20]. 
Overall impression of improvement in patient’s condition was rated 
by Clinicians Global Impression of Change score (CGIC) at the 
baseline and end of the 8 w [21]. It is a 7 point scale based on 
clinician observation, 1-very much improved, 2-much improved, 3-
minimally improved, 4-not changed, 5-minimally worse, 6-much 
worse and 7-very much worse. 
Patient Global Impression of Change score–PGIC. It is a 7 point scale 
was self-rated by the patient with 1-No change, 2-Almost the same, 
3-A little better, 4-Somewhat better, 5-Moderately better, 6-Better 
and a definite improvement, 7-A great deal better and a considerable 
improvement [22]. 
Statistical analysis 
The student t test (paired) was applied for intragroup changes from 
baseline and student t test (unpaired) was applied for intergroup 
comparison. p value of<0.05 was considered statistically significant.  
RESULTS 
A total of forty-eight patients of Postherpetic were enrolled and all 
completed the study.  
Medical outcomes study sleep scale (MOS) 
MOS sleep scale was significantly increased in both groups from 
baseline score (p<0.0001) (table 1) on intergroup comparison no 
statistically significant difference was observed (table 2). 
 
Table 1: Effect of pregabalin and nortriptyline on MOS sleep score 
Treatment group Baseline 2 w 4 w 8 w 
Pregabalin Group (n=24,Mean+SD)  35.54±3.01 41.38±.24#### 48.25±5.05#### 55.96±5.52#### 
 Nortriptyline Group (n=24,Mean+SD)  35±2.83 40.7±2.75#### 47.05±3.93#### 53.65±5.17#### 
The data is shown as mean±SD showing unpaired t test in comparison to respective baselines #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001, NS 
not significant 
 
Table 2: Comparative effect of pregabalin and nortriptyline on MOS sleep 
Duration Pregabalin group n= 24, mean+SD Nortriptyline group n= 24, mean+SD p value Statistical significance 
Baseline 35.54±3.01 35.0±2.83 0.525 NS 
2 W 41.38±3.24 40.7±2.75 0.437 NS 
4 W 48.25±5.05  47.05±3.93 0.363 NS 
8 W 55.96±5.52  53.6+5.17  0.141 NS 
The data is shown as mean±SD showing unpaired t test in comparison to respective baselines #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001, NS 
not significant 
 
Euro QOL-5D-5L Score evaluation revealed significant improvement 
in quality of life in both groups at 8 w (p<0.0001) (table 3). Only 
numerical decrease in pregabalin treated group was observed on 
comparison with nortriptyline (table 4). 
  
Table 3: Effect of pregabalin and nortriptyline on Euro quality of life 5D-5L score (EQ-5D-5L) 
 Treatment group Baseline 8 w 
 Pregabalin group (n=24 Mean+SD) 12.50±3.43 6.17±1.27#### 
 Nortriptyline (n=24 Mean+SD) 12.15±3.25 6.65±1.60#### 
The data is shown as mean±SD showing Paired t test in comparison to respective baselines #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001, NS not 
significant 
 
Table 4: Comparative effect of pregabalin and nortriptyline on quality of life score (EQ-5D-5L) 
Duration Pregabalin group  n= 24, mean+SD  Nortriptyline group n= 24, mean+SD p value Statistical significance 
Baseline 12.50±3.43 12.15±3.25 0.718 NS 
8 W  6.17±1.27 6.65±1.60 0.255 NS 
 The data is shown as mean±SD showing Paired t test in comparison to respective baselines #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001, NS 
not significant 
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Table 5: Effect of pregabalin and nortriptyline on CGIC score 
Treatment group Baseline 8 w 
Pregabalin (n=24, mean+SD)  5.79±0.72 1.33±0.48#### 
Nortriptyline(n=24, mean+SD)  6.0±0.37 2.00±0.97#### 
The data is shown as mean±S. D showing Paired t test in comparison to respective baselines #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001, NS 
not significant 
 
Table 6: Comparative effect of pregabalin and nortriptyline on clinicians global impression of change score (CGIC) 
Duration Pregabalin group n=24, mean+SD Nortriptyline group n= 24 mean+SD p-value Statistical significance 
Baseline 5.79±0.72 6.0±0.37  0.210 NS 
8 W 1.33± 0.48 2.00±0.97 0.004** S 
The data is shown as mean±SD showing the comparison between the groups at baseline and 8 w using student unpaired t test *p<0.05, **p<0.01, 
***p<0.001, NS not significant 
 
 
Fig. 1: Comparative effect of pregabalin and nortriptyline on PGIC score 
 
Clinicians global impression of change score (CGIC) 
Overall significant improvement in patient’s condition was observed 
by CGIC scale (p<0.0001) in both treatment groups (table 5). 
However, the intergroup comparison revealed more improvement 
with pregabalin at 8 w (P=0.004) (table 6). 
Patient global impression of change score (PGIC) 
Showed overall improvement in both the groups. On comparison, 
pregabalin had the dominant effect (P=0.0003). (fig. 1) 
DISCUSSION  
Neuropathic pain is known to adversely affect the quality of life and 
sleep and more than 50% of patients with PHN have sleep 
disturbances [23].  
In the present study, the effects of pregabalin and nortriptyline in 
patients of PHN on sleep and quality of life were evaluated. MOS 
sleep score and quality of life (EQ-5D-5L) were significantly 
improved by both pregabalin and nortriptyline.  
Sabatowski R et al. 2004 [24] have recorded reduced mean sleep 
interference scores and increased health-related quality-of-life 
(HRQoL) in patients of PHN receiving pregabalin (150 or 300 
mg/day). Effect was observed as early as first week and was 
maintained throughout the study of eight weeks.  
Similarly, other reports have also recorded an improvement in EQ-
5D-5L and sleep scores with Pregabalin in neuropathic pain. 
Improvements in sleep and quality of life were marginally related to 
the reduction in pain intensity. However, improvement in sleep 
quality was a significant predictor of better quality of life [25, 26]. 
Similar to our observations, improvement with pregabalin on 
domains of sleep disturbance and PGIC has also been reported [27]. 
Pregabalin is well documented to improve sleep parameters in 
painful conditions like fibromyalgia and also in generalized anxiety 
disorders [28]. Pregabalin primarily affects sleep maintenance and 
has a direct effect that is distinct from its analgesic, anxiolytic and 
anticonvulsant effects [29]. 
It is well recognized that most of the antidepressants lead to 
activation of serotonergic 5-HT2 receptors and increased 
noradrenergic and dopaminergic neurotransmission by modulating 
wakefulness, rapid eye movement and sleep duration. But 
antidepressants with prominent antihistaminic action increase sleep 
continuity like sedative TCA (amitriptyline, doxepin, trimipramine) 
and sedative antidepressants (mirtazapine, trazodone, nefazodone, 
mianserine). These antidepressants with strong antagonism at 
serotonergic 5-HT2A receptors in some patients show improvement 
of sleep quality even after the first drug dose [30].  
In the present trial CGIC scores were found to be reduced while PGIC 
scores increased. Our results are in agreement with another study 
showing improvement on these parameters by pregabalin [31]. On 
comparing, pregabalin was found to be more effective than 
nortriptyline at 8 w on various parameters CGIC (p=0.005) and PGIC 
score (p=0.0003). Achar A et al., 2013 [32] has recorded 
improvement with pregabalin in PHN patients.  
Current study suffers from few limitations of being the short 
duration of 8 w and had a small sample size. 
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CONCLUSION 
Both pregabalin and nortriptyline were effective in improving sleep, 
quality of life and overall condition in PHN. Pregabalin was found to 
be better than nortriptyline at 8 w on CGIC and PGIC scales and it 
could be a promising option, though more trials in the future with 
large sample size and longer duration are needed.  
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